$-0.04 EPS Expected for Amarin plc (AMRN); Spherix (SPEX) SI Decreased By 11.86%

February 15, 2018 - By William Brooks

Spherix (NASDAQ:SPEX) had a decrease of 11.86% in short interest. SPEX’s SI was 555,300 shares in February as released by FINRA. Its down 11.86% from 630,000 shares previously. With 165,000 avg volume, 3 days are for Spherix (NASDAQ:SPEX)’s short sellers to cover SPEX’s short positions. The SI to Spherix’s float is 11.59%. The stock decreased 0.76% or $0.01 during the last trading session, reaching $1.31. About 35,108 shares traded. Spherix Incorporated (NASDAQ:SPEX) has declined 46.60% since February 15, 2017 and is downtrending. It has underperformed by 63.30% the S&P500.

Analysts expect Amarin Corporation plc (NASDAQ:AMRN) to report $-0.04 EPS on February, 27.They anticipate $0.01 EPS change or 20.00% from last quarter’s $-0.05 EPS. After having $-0.04 EPS previously, Amarin Corporation plc’s analysts see 0.00% EPS growth. The stock increased 2.83% or $0.1 during the last trading session, reaching $3.63. About 1.29M shares traded. Amarin Corporation plc (NASDAQ:AMRN) has risen 76.19% since February 15, 2017 and is uptrending. It has outperformed by 59.49% the S&P500.

Spherix Incorporated, an intellectual property company, owns, develops, acquires, and monetizes patented and unpatented intellectual properties. The company has market cap of $8.17 million. The firm owns approximately 290 patents and patent applications. It currently has negative earnings. The Company’s patent portfolio includes the U.S. and foreign patents and pending patent applications in the wireless communications and telecommunication sectors, including data, optical and voice technology, antenna technology, Wi-Fi, base station functionality, and cellular.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company has market cap of $1.05 billion. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It currently has negative earnings. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.

Among 4 analysts covering Amarin Corp (NASDAQ:AMRN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amarin Corp had 13 analyst reports since May 12, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 3 by H.C. Wainwright. The firm earned “Buy” rating on Monday, June 12 by Cantor Fitzgerald. The company was maintained on Thursday, November 2 by H.C. Wainwright. The stock of Amarin Corporation plc (NASDAQ:AMRN) earned “Buy” rating by Cantor Fitzgerald on Wednesday, October 5. The rating was initiated by Jefferies with “Buy” on Thursday, May 12. The stock has “Buy” rating by H.C. Wainwright on Thursday, June 1. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, August 29. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, August 14. The stock of Amarin Corporation plc (NASDAQ:AMRN) earned “Buy” rating by H.C. Wainwright on Tuesday, June 27. The company was maintained on Monday, June 12 by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 William Brooks

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: